Anixa Biosciences Inc (ANIX) stock
Close on Nov 12, 2026Market cap $93.17MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $93.17M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.44
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$10.38M
- EPS, diluted
- -$0.34
- Book value per share
- $0.42
- Diluted shares
- 34M
Trading
- Previous close
- $2.78
- Open
- $2.72
- Day's range
- $2.66 – $2.85
- Volume
- 276,283
- Average volume (20 days)
- 190,102
- Beta (5 years)
- 0.64
- 52-week range
- $2.32 – $5.46
- RSI (14 days)
- 40.8
- Volatility (1 year)
- 66.7%
- Relative volume
- 1.03×
- WACC
- 8.1%
On 2 of our idea lists: Insider cluster buys, Insiders buying the dip
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANIX | S&P 500 | Difference | ANIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.6% | -2.7% | −2.9 pts | ||
| 3 months | -17.0% | -1.7% | −15.3 pts | ||
| Year to date | -14.1% | +11.9% | −26.0 pts | ||
| 1 year | -39.0% | +12.0% | −50.9 pts | ||
| 3 years | -8.5% | +78.2% | −86.7 pts | -2.9% | +21.2% |
| 5 years | -42.7% | +73.2% | −116.0 pts | -10.6% | +11.6% |
| 10 years | -53.8% | +309.6% | −363.4 pts | -7.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Anixa Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Anixa Biosciences
Pharmaceutical Preparations
Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology. The company's therapeutics portfolio includes liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy targeting ovarian cancer that is being developed through its Certainty Therapeutics subsidiary in collaboration with the Moffitt Cancer Center. Its vaccine programs feature an investigational breast cancer vaccine targeting alpha-lactalbumin, developed alongside the Cleveland Clinic, as well as an ovarian cancer vaccine targeting the anti-Mullerian hormone receptor 2 protein extracellular domain. Anixa also conducts discovery work to identify vaccine targets for lung, colon, and prostate cancers.
Company profile, executives and historyAnixa Biosciences stock: common questions
What is Anixa Biosciences's stock price?
ANIX closed at $2.68 on Nov 12, 2026, down 3.60% on the day. Over the past 52 weeks it traded between $2.32 and $5.46.
What is Anixa Biosciences's market cap?
Anixa Biosciences was worth $93.17M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ANIX's P/E ratio?
Anixa Biosciences lost money over fiscal 2025 (diluted EPS -$0.34), so it has no meaningful P/E ratio.
Does Anixa Biosciences pay a dividend?
No. Anixa Biosciences has not paid a cash dividend over the last twelve months.
How has ANIX stock performed over the past year?
Including dividends, ANIX returned -39.0% over the past year, against +12.0% for the S&P 500.
How many ANIX shares are sold short?
2M shares were sold short at the latest FINRA report, 6.54% of the float, or 8.4 days of average trading volume.
Who are Anixa Biosciences's competitors?
Companies most similar to Anixa Biosciences by business, industry and size include APVO, BCTX, XBIO, VCNX, ELTX.
See a number that looks wrong?